Palvella Therapeutics Inc. (NASDAQ: PVLA) presented two poster studies at the American Academy of Dermatology Annual Meeting held March 27-31 in Denver, Colorado, according to a company statement.

The first poster detailed the company's QTORIN rapamycin formulation, a single-phase anhydrous gel designed to address crystallization and stability issues with rapamycin in topical applications. The study showed that compounded rapamycin formulations demonstrated drug crystallization and rapid chemical degradation, while QTORIN rapamycin aims to optimize dermal bioavailability for mTOR-driven skin diseases.

The poster referenced the Phase 3 SELVA study results, where QTORIN rapamycin in microcystic lymphatic malformations met its primary endpoint with statistical significance (p<0.001) on the Microcystic Lymphatic Malformation Investigator Global Assessment, as well as all secondary endpoints. Systemic rapamycin levels remained below 2ng/mL at all measured timepoints.

The second poster presented findings from qualitative interviews with nine patients and one caregiver about porokeratosis, a rare genetic skin disease. The interviews documented physical symptoms including widespread lesions with redness, scaling and itching, along with psychosocial impacts such as social isolation and anxiety about cancer risk. Some participants reported skin cancer diagnoses resulting from lesion transformation.

Palvella is developing QTORIN rapamycin for multiple rare skin diseases and vascular malformations, with a fourth indication expected to be announced in the second half of 2026. The company plans to begin a Phase 2 trial of QTORIN pitavastatin for disseminated superficial actinic porokeratosis in the second half of 2026.

No FDA-approved therapies currently exist for the conditions Palvella is targeting, which the company estimates affects more than 50,000 diagnosed patients in the United States for porokeratosis alone.